Effect of erythropoietin therapy on red cells filterability and left ventricular mass in predialysis patients

Kamal Hassan, Nathan Roguin, Yan Kaganov, Shadi Hasan, Batya Kristal

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Background. Cardiovascular complications are the leading cause of mortality in patients with end-stage renal disease. Left ventricular hypertrophy (LVH) is recognized as an independent risk factor for cardiovascular morbidity and mortality. At the onset of dialysis, more than 70% of the patients with chronic kidney disease have echocardiographic evidence of LVH. Anemia, increased red cells filterability time (RCFT), and blood viscosity are known to induce LVH. Aim. To evaluate, prospectively, the effects of erythropoietin (EPO) therapy for 20 weeks on RCFT and left ventricular mass (LVM). Patients and Methods. Twenty uremic and anemic predialysis patients with creatinine clearance test below 35 mL/min were studied. RCFT test and three-dimensional echocardiography were performed at 0, 10, and 20 weeks. Results. EPO therapy for 20 weeks did not adversely affect renal function and did not significantly change the mean blood pressure. It significantly increased the hemoglobin and fibrinogen levels, and decreased RCFT and LVM (p < .01). Conclusion. Although correction of anemia can contribute to regression of LVM, we speculate that an increasing number of cells with normalized viscoelastic properties and a direct effect of EPO on erythrocytes and myocardiocytes, through specific receptors, may also play an important role.

Original languageEnglish
Pages (from-to)177-182
Number of pages6
JournalRenal Failure
Issue number2
StatePublished - 2005
Externally publishedYes


  • Deformability
  • Filterability
  • Predialysis
  • Rheology
  • Ventricular mass


Dive into the research topics of 'Effect of erythropoietin therapy on red cells filterability and left ventricular mass in predialysis patients'. Together they form a unique fingerprint.

Cite this